ViewpointMT

Viewpoint is a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents.

[ViewpointMT @Viewpoint_MT]

Viewpoint Molecular Targeting is presenting at #BiotechShowcase! Join us in San Francisco this January 9th at 10:00 am PST to attend our presentation about our pipeline featuring our leading lead-212-based alpha-particle radiotherapies. Register: https://t.co/iqRSKOKKoj

[ViewpointMT @Viewpoint_MT]

Have you seen our new MOA video? If not, be sure to check it out here: https://t.co/uGV2GLXABA

#Theranostics #Radiopharmaceuticals #MetastaticMelanoma #NeuroendocrineTumors

[ViewpointMT @Viewpoint_MT]

Have you seen our new MOA video? If not, be sure to check it out here: https://t.co/uGV2GLXABA

#Theranostics #Radiopharmaceuticals #MetastaticMelanoma #NeuroendocrineTumors

[ViewpointMT @Viewpoint_MT]

Viewpoint Molecular Targeting® to Present at the B. Riley Radiation Oncology Investor Day.

https://t.co/VST7yEyuuQ
@BRileyFinancial #Theragnostics #Radiopharmaceuticals #Radiotherapy

[ViewpointMT @Viewpoint_MT]

Viewpoint Molecular Targeting® Appoints Thijs Spoor as Chief Executive Officer.

https://t.co/1cwbvrUFvj
#Theragnostics #Radiopharmaceuticals #Radiotherapy

[ViewpointMT @Viewpoint_MT]

Sign up for email alerts to stay up to date with our latest communications and happenings! https://t.co/zaTsD2GYYR

#Radiopharmaceuticals #Theranostics

[ViewpointMT @Viewpoint_MT]

4 in 10 #cancer diagnoses in the U.S. are associated with preventable risk factors. In recognition of #NationalCancerPreventionMonth, we encourage you to learn more at https://t.co/YVRduBbC4Q.

@AACRFoundation

[ViewpointMT @Viewpoint_MT]

Today is #WorldCancerDay. This year’s focus is on understanding and recognizing the inequities in cancer care around the globe. Learn more and how you can help to #CloseTheCareGap here: https://t.co/2QmcId76Gd

#Radiopharmaceuticals #Theranostics

[ViewpointMT @Viewpoint_MT]

Dr. Michael K. Schultz, Co-Founder and Chief Science Officer of Viewpoint, provides insight behind the power of theranostics to cancer therapy.

@InvestorVirtual #VirtualInvestor #Theranostics #Radiopharmaceuticals #MetastaticMelanoma #NeuroendocrineTumors

[ViewpointMT @Viewpoint_MT]

We are presenting today at 11:00 AM ET at the JTC #VirtualInvestor 2022 Top Picks Conference. Access our webcast at https://t.co/iM9C4OxiA7

@InvestorVirtual

[ViewpointMT @Viewpoint_MT]

#DontMissIt! We are presenting at the upcoming JTC #VirtualInvestor 2022 Top Picks Conference on Tuesday, January 25th at 11:00 AM ET. Pre-submit your questions here: https://t.co/Hx1rBZp4kN

@InvestorVirtual

[ViewpointMT @Viewpoint_MT]

Viewpoint Molecular Targeting® to Present at the Virtual Investor 2022 Top Picks Conference.

https://t.co/mTjZpHHYdu
@InvestorVirtual #VirtualInvestor

[ViewpointMT @Viewpoint_MT]

Our Co-Founder and CSO, Dr. Michael K. Schultz, has confidence in the Company’s approach to developing alpha-particle #radiopharmaceuticals.

#Theranostics #MetastaticMelanoma #NeuroendocrineTumors @InvestorVirtual #VirtualInvestor

[ViewpointMT @Viewpoint_MT]

Have you seen our new MOA video? If not, be sure to check it out here: https://t.co/uGV2GLXABA

#Theranostics #Radiopharmaceuticals #MetastaticMelanoma #NeuroendocrineTumors

[Virtual Investor Co. @InvestorVirtual]

We are hosting the 2022 Top Picks Conference January 25-27, 2022. Access the event, its schedule and pre-submit questions at: https://t.co/CIdWWxBH3a

$AEZS $AREC $AIM $CZO $CRBP $CNSP $CYTH $NVNO @iTolerance_inc @Melzi_Surgical $MBRX $OTLK $SING $VLON @Viewpoint_MT $XBIO

[ViewpointMT @Viewpoint_MT]

Our Co-Founder and CEO, Dr. Frances L. Johnson, highlights our unique approach to developing #radiopharmaceuticals.

#Theranostics #MetastaticMelanoma #NeuroendocrineTumors @InvestorVirtual #VirtualInvestor

[ViewpointMT @Viewpoint_MT]

#DontMissIt: Our presentation at the H.C. Wainwright BioConnect Conference is now available! Access the webcast here: https://t.co/Fy6RbwnyUi

@HCWCO #HCWCO

[ViewpointMT @Viewpoint_MT]

#MarkYourCalendars: We are participating in the upcoming H.C. Wainwright BioConnect Conference. Access the event here: https://t.co/Fy6RbwnyUi

@HCWCO #HCWCO

[ViewpointMT @Viewpoint_MT]

Viewpoint Molecular Targeting® to Present at the H.C. Wainwright BioConnect Conference.

https://t.co/0iEmryyB1m
@HCWCO #HCWCO #Radiopharmaceuticals #Theranostics #MetastaticMelanoma #NeuroendocrineTumors

[ViewpointMT @Viewpoint_MT]

Wishing you a prosperous New Year!